BioSpace News Archive

Plus, what to expect in a phone screen and how to handle an impending layoff.

From gene-corrected cell therapies to a new CAR-T, the cell and gene therapy space looks to expand its reach into the market.

The first Bioversity cohort includes several graduates placed at Massachusetts life sciences companies.

Looking for oncology jobs in the biopharma industry? Check out these five top companies hiring life sciences professionals like you.

Sanofi’s CD40L antibody, frexalimab, demonstrated sustained reduction of disease activity and favorable tolerability after nearly one year in participants with relapsing multiple sclerosis.

Novartis announced data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta® treatment for up to six years in recently diagnosed – defined as starting treatment within three years of initial diagnosis – treatment-naïve people living with relapsing multiple sclerosis.

TScan Therapeutics, Inc. announced the pricing of an underwritten public offering of 2,472,581 shares of its voting common stock at a public offering price of the market price of $7.1300 per share, which was equal to the closing price of its voting common stock on the Nasdaq Global Market on April 16, 2024.

Evotec SE announced the appointment of Aurélie Dalbiez as the Company’s new Chief People Officer, effective 15 June 2024.

Essential Pharma announces that it has completed the acquisition of Reminyl® oral capsules from Janssen Pharmaceutica NV, a Johnson & Johnson company.

Sound Bioventures announced a new investment in Theolytics, a UK biotechnology company developing next-generation oncolytic viral therapies.